Verona Pharma company information, Employees & Contact Information

Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales GlobeNewswire

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 Yahoo Finance

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade Business Wire

Merck to Acquire Verona Pharma citybiz

Verona Pharma Secures Speaking Slots at Two Major Healthcare Investor Conferences This June Stock Titan

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update Yahoo Finance

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)* PR Newswire

$10 Billion Respiratory Disease Deal: Merck to Acquire Verona Pharma After 99.5% Shareholder Approval Stock Titan

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD Yahoo Finance

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 GlobeNewswire

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides GlobeNewswire

First Novel COPD Treatment in 20 Years: Verona's Ohtuvayre Shows Dual Action in Phase 3 ENHANCE Studies Stock Titan

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update Stock Titan

Verona's COPD Drug Ohtuvayre Crushes Expectations with 95% Sales Growth, 25,000 Q1 Prescriptions Stock Titan

$10B deal: Verona Pharma to be acquired by MSD for $107/ADS after High Court approval Stock Titan

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS GlobeNewswire

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) GlobeNewswire

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital GlobeNewswire

Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update Yahoo Finance

Verona Pharma Lands Massive $450M Financing Deal as COPD Drug Success Drives Growth Stock Titan

Merck to acquire Verona Pharma - 07:00:08 09 Jul 2025 - RTW News article London Stock Exchange

Verona Pharma Receives $650M Investment from Oaktree Capital Management and OMERS Life Sciences Pharmaceutical Executive

Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD Yahoo Finance

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance GlobeNewswire

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition (NASDAQ:VRNA) Seeking Alpha

Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD GlobeNewswire

PDMR Dealing GlobeNewswire

Verona Pharma Announces Departure of Chief Medical Officer GlobeNewswire

Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China Laotian Times

UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M Labiotech.eu

Respiratory disease: asthma and chronic obstructive pulmonary disease Understanding Animal Research

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug Labiotech.eu

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma News-Medical